The newly-launched UCLA spinout is targeting rare and treatment-resistant forms of epilepsy with an approach drawing on certain kinds of gut bacteria.
Bloom Science, a US-based epilepsy therapy spinout from University of California, Los Angeles (UCLA), launched last Thursday with a seed round of undisclosed size backed by unnamed industry investors.
Bloom has agreed an exclusive licence with UCLA Technology Development Group, the university’s tech transfer office, to develop a biotherapeutic product that mimics the seizure-checking effects of the ketogenic diet.
The high-fat, low-carbohydrate regimen has been used to combat rare and treatment-resistant forms of epilepsy since the 1920s. It works by…
